PH12019502110A1 - Pharmaceutical combination comprising ponesimod - Google Patents

Pharmaceutical combination comprising ponesimod

Info

Publication number
PH12019502110A1
PH12019502110A1 PH12019502110A PH12019502110A PH12019502110A1 PH 12019502110 A1 PH12019502110 A1 PH 12019502110A1 PH 12019502110 A PH12019502110 A PH 12019502110A PH 12019502110 A PH12019502110 A PH 12019502110A PH 12019502110 A1 PH12019502110 A1 PH 12019502110A1
Authority
PH
Philippines
Prior art keywords
ponesimod
pharmaceutical combination
active ingredient
teriflunomide
leflunomide
Prior art date
Application number
PH12019502110A
Other languages
English (en)
Inventor
Martine Clozel
Laetitia Pouzol
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of PH12019502110A1 publication Critical patent/PH12019502110A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
PH12019502110A 2017-03-14 2019-09-13 Pharmaceutical combination comprising ponesimod PH12019502110A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2017055994 2017-03-14
PCT/EP2018/056185 WO2018167030A1 (en) 2017-03-14 2018-03-13 Pharmaceutical combination comprising ponesimod

Publications (1)

Publication Number Publication Date
PH12019502110A1 true PH12019502110A1 (en) 2020-03-16

Family

ID=61655772

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12019502110A PH12019502110A1 (en) 2017-03-14 2019-09-13 Pharmaceutical combination comprising ponesimod

Country Status (24)

Country Link
US (3) US11723896B2 (cg-RX-API-DMAC7.html)
EP (1) EP3595657A1 (cg-RX-API-DMAC7.html)
JP (3) JP7281406B2 (cg-RX-API-DMAC7.html)
KR (1) KR102574562B1 (cg-RX-API-DMAC7.html)
CN (1) CN110381942B (cg-RX-API-DMAC7.html)
AU (2) AU2018233109B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019018894A2 (cg-RX-API-DMAC7.html)
CA (1) CA3056301C (cg-RX-API-DMAC7.html)
CL (1) CL2019002525A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019008510A2 (cg-RX-API-DMAC7.html)
CR (1) CR20190464A (cg-RX-API-DMAC7.html)
DO (1) DOP2019000257A (cg-RX-API-DMAC7.html)
EA (1) EA201992117A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP19073317A (cg-RX-API-DMAC7.html)
IL (1) IL269239B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20190207A1 (cg-RX-API-DMAC7.html)
MA (1) MA49822A (cg-RX-API-DMAC7.html)
MX (1) MX390941B (cg-RX-API-DMAC7.html)
NI (1) NI201900092A (cg-RX-API-DMAC7.html)
PE (1) PE20191489A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019502110A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201907308UA (cg-RX-API-DMAC7.html)
UA (1) UA125756C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018167030A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190207A1 (ar) * 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES448386A1 (es) 1975-06-05 1978-04-16 Hoechst Ag Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico.
DE2854439A1 (de) 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
US5268382A (en) 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
ES2237553T3 (es) 2000-02-15 2005-08-01 Teva Pharmaceutical Industries Ltd. Procedimiento para la sintesis de leflunomida.
EP1381356B1 (en) * 2001-04-05 2008-05-28 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US6894184B2 (en) 2003-03-18 2005-05-17 Aventis Pharma Deutschland Gmbh Process for preparing 2-cyano-3-hydroxy-N-(phenyl)but-2-enamides
USRE43728E1 (en) 2003-11-21 2012-10-09 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
AU2005295511A1 (en) 2004-10-19 2006-04-27 Aventis Pharmaceuticals Inc. Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
DE102006017896A1 (de) 2006-04-13 2007-10-25 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Leflunomid enthaltende pharmazeutische Zusammensetzungen
TWI460166B (zh) 2006-11-23 2014-11-11 Actelion Pharmaceuticals Ltd 製備２-亞胺基-四氫噻唑-４-酮衍生物之新穎方法
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
PL2278960T5 (pl) * 2008-03-17 2020-06-29 Actelion Pharmaceuticals Ltd. Schemat dawkowania dla selektywnego agonisty receptora sip1
GB0819182D0 (en) 2008-10-20 2008-11-26 Actelion Pharmaceuticals Ltd Crystalline forms
NZ598744A (en) 2009-09-18 2013-11-29 Sanofi Sa (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
JP2013533286A (ja) 2010-07-30 2013-08-22 セントルイス ユニバーシティ 疼痛を治療する方法
WO2012018704A1 (en) 2010-08-02 2012-02-09 Sanofi-Aventis U.S. Llc Use of teriflunomide for treating multiple sclerosis
EP2692343A1 (en) 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
SMT202000298T1 (it) 2012-08-17 2020-07-08 Actelion Pharmaceuticals Ltd Processo per la produzione di (2z,5z)-5-(3-cloro-4((r)-2,3-diidrossipropossi) benziliden)-2-(propilimmino)-3-(o-tolil)tiazolidin-4-one e intermedio usato in detto processo
WO2016079687A1 (en) 2014-11-18 2016-05-26 Lupin Limited Oral pharmaceutical composition of teriflunomide
KR20200013086A (ko) 2014-12-11 2020-02-05 액테리온 파마슈티칼 리미티드 선택적 s1p1 수용체 효능제에 대한 투약 섭생
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
US20180185308A1 (en) 2015-06-18 2018-07-05 Matinas Biopharma Nanotechnologies, Inc. Compositions and methods for treating inflammatory disease or conditions
JOP20190207A1 (ar) * 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود

Also Published As

Publication number Publication date
AU2018233109A1 (en) 2019-08-22
CA3056301A1 (en) 2018-09-20
EA201992117A1 (ru) 2020-02-17
JP2024096962A (ja) 2024-07-17
KR20190122716A (ko) 2019-10-30
MX2019010874A (es) 2019-12-11
KR102574562B1 (ko) 2023-09-04
US12527772B2 (en) 2026-01-20
US20200069655A1 (en) 2020-03-05
AU2018233109B2 (en) 2023-09-28
US20240139161A1 (en) 2024-05-02
IL269239B1 (en) 2023-03-01
SG11201907308UA (en) 2019-09-27
IL269239A (en) 2019-11-28
MA49822A (fr) 2020-06-17
US11723896B2 (en) 2023-08-15
CO2019008510A2 (es) 2019-10-21
ECSP19073317A (es) 2019-11-30
NI201900092A (es) 2020-03-11
WO2018167030A1 (en) 2018-09-20
CN110381942B (zh) 2022-12-27
CL2019002525A1 (es) 2020-02-07
PE20191489A1 (es) 2019-10-21
CR20190464A (es) 2019-11-26
US20260108501A1 (en) 2026-04-23
JOP20190207A1 (ar) 2019-09-10
JP2023030091A (ja) 2023-03-07
CN110381942A (zh) 2019-10-25
JP7281406B2 (ja) 2023-05-25
CA3056301C (en) 2024-10-01
JP2020510045A (ja) 2020-04-02
IL269239B2 (en) 2023-07-01
DOP2019000257A (es) 2020-09-15
UA125756C2 (uk) 2022-06-01
BR112019018894A2 (pt) 2020-04-14
AU2023274118A1 (en) 2023-12-21
EP3595657A1 (en) 2020-01-22
AU2023274118B2 (en) 2024-12-12
MX390941B (es) 2025-03-21

Similar Documents

Publication Publication Date Title
PH12019502110A1 (en) Pharmaceutical combination comprising ponesimod
MX2023011657A (es) Composiciones que comprenden curones y usos de los mismos.
MX2021000965A (es) Composiciones que comprenden polirribonucleotidos circulares y usos de estas.
PL3668937T3 (pl) Kompozycje i zastosowania Z-1-chloro-2,3,3,3-tetrafluoroprop-1-enu
SA520411187B1 (ar) نظائر فينيل ألانينول كربامويل واستخداماتها
GB2581117B (en) Dynamic delivery of software functions
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
MY192425A (en) Polymorphs
GEP20217318B (en) Pyrazole magl inhibitors
NZ769658A (en) Anti-influenza virus agent for suppressing aggravation of influenza
MX2020005483A (es) Antagonistas de ildr2 y combinaciones de los mismos.
MY199913A (en) Pharmaceutical combination comprising a t-type calcium channel blocker
EP3573747A4 (en) PREPARATION OF MICROPARTICLES OF AN ACTIVE SUBSTANCE
GB2552733B (en) Aerosol compositions having improved active ingredient application
MY181719A (en) Fragrance and flavor compositions comprising neopentyl glycol diacetate
MX376853B (es) Odorante osmanthus.
MX2014008336A (es) Combinacion farmacologica antihiperalgesica, antialodinica y antiinflamatoria, composiciones farmaceuticas que la contienen, y su uso para el tratamiento del dolor neuropatico.
WO2018237010A3 (en) VACCINE COMPOSITIONS AGAINST STREPTOCOCCUS AND THEIR METHODS OF USE
GB2554966B (en) Deodorizing combination of active ingredients
PH12019500024A1 (en) Pharmaceutical compositions
MY202239A (en) Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
MX2020003513A (es) Composiciones de ingredientes activos que comprenden n-alquenoil-n-alquilglucamidas y el uso de los mismos.
MX2020004731A (es) Terapias de combinacion de inhibidor ezh2.
TR201620309A2 (tr) Metformi̇n hi̇droklori̇t ve pi̇ogli̇tazon hi̇droklori̇ti̇n farmasöti̇k bi̇leşi̇mleri̇
HK40019968A (en) Dosage forms of tissue kallikrein 1